Kenton Forte, MD
General Practice · Buffalo, NYNPI 1326023953
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $114,418 of the $144,405 with a category attached, or 79.2%. Amarin Pharma, Inc. accounts for 71.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $96,321 and has fallen 99.4% since, to $599 in 2025. Among general practice clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $681.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$104K
- Amgen$36K
- Romark Laboratories, LC$3K
- Kestra Medical Technology Services, Inc.$939
- Johnson & Johnson$263
- Boston Scientific$259
- plus $623 from 12 others
What the payments were for
- Speaking & faculty fees$114,41879%
- Travel & lodging$20,30814%
- Food & beverage$6,6675%
- Education$120%
- Ownership interest$3,0002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 120 | $103,685 |
| Amgen | 35 | $35,636 |
| Romark Laboratories, LC | 1 | $3,000 |
| Kestra Medical Technology Services, Inc. | 21 | $939 |
| Johnson & Johnson | 6 | $263 |
| Boston Scientific | 4 | $259 |
| Impulse Dynamics (USA) Inc. | 2 | $139 |
| AstraZeneca | 4 | $115 |
| Boehringer Ingelheim | 4 | $88 |
| Pfizer | 4 | $69 |
| Biotronik Inc. | 3 | $48 |
| Abbott | 1 | $34 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Novartis | 1 | $27 |
| Bayer | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$102,251
- Repatha$35,556
- Alinia$9,000
- OPTIMIZER$233
- WATCHMAN FLX$152
- XARELTO$134
- INVOKANA$134
- Assure WCD$130
How this compares
$144,405 in reported general payments places this provider in the 95th percentile of 5,764 general practice providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 43 | $62,504 |
| JardianceEmpagliflozin | 14 | $16,107 |
| XareltoRivaroxaban | 13 | $11,958 |
| Icosapent Ethyl | 35 | $10,179 |
| VascepaIcosapent Ethyl | 15 | $8,772 |
| JanuviaSitagliptin Phosphate | 11 | $7,960 |
| Carvedilol ErCarvedilol Phosphate | 14 | $4,742 |
| Irbesartan | 127 | $3,669 |
| Rosuvastatin Calcium | 152 | $2,817 |
| Carvedilol | 164 | $1,988 |
| Ezetimibe | 55 | $1,812 |
| Amlodipine Besylate | 174 | $1,490 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 51 | $1,443 |
| Metoprolol Succinate | 64 | $1,412 |
| Nifedipine ErNifedipine | 78 | $1,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $69 | $62,50443 claims |
| Boehringer IngelheimJardiance | $88 | $16,10714 claims |
| Johnson & JohnsonXarelto | $263 | $11,95813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,764 general practice providers in New York.
Other general practice in Buffalo
- Michael DanielakBuffalo$197K
- Sebastiano AndreanaBuffalo$14K
- Mark HochmanHicksville$5.1M
- David RiceEast Amherst$1.2M
- Brian JacksonUtica$477K
- Ronnie MyersNew York$464K
- Ira LangsteinWhite Plains$422K
- Benedict MiragliaMount Kisco$378K
- Michael MashaalRoslyn$262K
- William RomeroDix Hills$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.